Want to see HK:6618 full AI Analyst Report?
6618 Stock Chart & Stats
HK$37.00
HK$0.78(2.11%)
At close: 4:00 PM EDT
HK$37.00
HK$0.78(2.11%)
Day’s Range― - ―
52-Week RangeHK$31.84 - HK$71.70
Previous CloseN/A
Volume4.55M
Average Volume (3M)7.60M
Market Cap
HK$126.52B
Enterprise ValueHK$124.80K
Total Cash (Recent Filing)HK$48.15B
Total Debt (Recent Filing)HK$636.29M
Price to Earnings (P/E)20.2
Beta1.40
Next Earnings
Aug 13, 2026EPS Estimate
1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.68
Shares Outstanding3,211,075,200
10 Day Avg. Volume6,883,323
30 Day Avg. Volume7,596,953
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)2.65
Price to Sales (P/S)2.17
P/FCF Ratio16.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$67.25Price Target Upside81.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.8
Revenue Forecast (FY)HK$86.38B
Bulls Say, Bears Say
Bulls Say
Low-leverage Balance SheetExceptionally low leverage and meaningful equity growth provide durable financial flexibility. This conservative capital structure supports continued investment in supply chain, AI and offline expansion while reducing refinancing and solvency risks, improving resilience through economic cycles.
Sustained Revenue & Profit GrowthConsistent double-digit top-line and faster profit growth indicate durable demand and improving unit economics. Margin expansion from scale and higher profitability from earlier loss making years creates a stronger earnings base to fund R&D, AI commercialization and measured offline rollout.
Large User Base & Product ScaleA large, growing user base and expanding product/AI footprint create sustainable competitive advantages: network effects, cross-sell opportunities and high engagement that can drive recurring service revenue and scale benefits in fulfillment and supply chain over multiple years.
Bears Say
Free Cash Flow InconsistencyA 2025 free-cash-flow reset to zero signals a structural shift in investment or working-capital needs. Even with strong operating cash flow, uneven cash conversion reduces near-term flexibility for discretionary investments, dividends or opportunistic M&A and raises execution risk.
Direct-sales Revenue ConcentrationHigh concentration in direct sales exposes the business to supplier, category or demand shocks in a few product lines. This structural dependency limits revenue diversification and can amplify margin and working-capital volatility if competitive or regulatory dynamics shift.
AI Monetization And Offline Economics UncertainWhile AI and offline channels scale engagement, their commercialization remains unproven. Monetization timelines for doctor-facing AI and the lower-margin economics of self-operated pharmacies create execution risk and could require sustained investment, pressuring near-term returns.
JD Health International, Inc. News
6618 FAQ
What was JD Health International, Inc.’s price range in the past 12 months?
JD Health International, Inc. lowest stock price was HK$31.84 and its highest was HK$71.70 in the past 12 months.
What is JD Health International, Inc.’s market cap?
JD Health International, Inc.’s market cap is HK$126.52B.
When is JD Health International, Inc.’s upcoming earnings report date?
JD Health International, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 4 days.
How were JD Health International, Inc.’s earnings last quarter?
JD Health International, Inc. released its earnings results on Mar 05, 2026. The company reported HK$1.087 earnings per share for the quarter, beating the consensus estimate of HK$0.756 by HK$0.331.
Is JD Health International, Inc. overvalued?
According to Wall Street analysts JD Health International, Inc.’s price is currently Undervalued.
Does JD Health International, Inc. pay dividends?
JD Health International, Inc. does not currently pay dividends.
What is JD Health International, Inc.’s EPS estimate?
JD Health International, Inc.’s EPS estimate is 1.36.
How many shares outstanding does JD Health International, Inc. have?
JD Health International, Inc. has 3,211,075,200 shares outstanding.
What happened to JD Health International, Inc.’s price movement after its last earnings report?
JD Health International, Inc. reported an EPS of HK$1.087 in its last earnings report, beating expectations of HK$0.756. Following the earnings report the stock price went down -6.219%.
Which hedge fund is a major shareholder of JD Health International, Inc.?
Currently, no hedge funds are holding shares in HK:6618
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JD Health International, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.80%
Trailing 12-Months
Company Description
JD Health International, Inc.
JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as over-the-counter and prescription medications, medical devices, and health supplements. These goods are distributed through both direct sales and an extensive online retail pharmacy network. Beyond product offerings, its comprehensive service suite includes virtual medical consultations, patient referrals to hospitals and doctors, health screening programs, genetic testing, and beauty care services. Additionally, it develops intelligent healthcare and wellness management solutions, alongside providing technical support and advertising services. The platform also facilitates access to various medical provisions, including general health examinations, cosmetic medical procedures, vaccination bookings, dental treatments, and nucleic acid testing. Incorporated in 2018 and headquartered in Beijing, People's Republic of China, JD Health International Inc. is a subsidiary of JD Jiankang Limited.
6618 Stock 12 Month Forecast
Average Price Target
HK$67.25
▲(81.76% Upside)
Technical Analysis
Kindstar Globalgene Technology, Inc.
―
Jinxin Fertility Group Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―